MedTrace Logo

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

NCT01165541 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to test whether taking two medicines (quetiapine and mirtazapine) is better for helping people to decrease drinking than taking one medicine alone (quetiapine).

Conditions

  • Alcohol Dependence

Interventions

DRUG

Mirtazapine

mirtazapine (7.5-45mg)

DRUG

Quetiapine fumarate extended release (Quetiapine XR)

Quetiapine fumarate extended release 50-400mg/d

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Principal Investigators

  • Mary Brunette, MD · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165541 on ClinicalTrials.gov